ACM
Altium Capital Management Portfolio holdings
AUM
$34.4M
1-Year Return
2.5%
This Quarter Return
-0.07%
1 Year Return
-2.5%
3 Year Return
+357.21%
5 Year Return
–
10 Year Return
–
AUM
$375M
AUM Growth
-$56.3M
(-13%)
Cap. Flow
-$44.2M
Cap. Flow
% of AUM
-11.78%
Top 10 Holdings %
Top 10 Hldgs %
22.52%
Holding
176
New
38
Increased
28
Reduced
15
Closed
52
Top Buys
| 1 |
Keros Therapeutics
KROS
|
$4.99M |
| 2 |
Celldex Therapeutics
CLDX
|
$4.96M |
| 3 |
X4 Pharmaceuticals
XFOR
|
$4.26M |
| 4 |
AFMD
Affimed
AFMD
|
$4.11M |
| 5 |
BCYC
Bicycle Therapeutics
BCYC
|
$3.83M |
Top Sells
| 1 |
ISEE
IVERIC bio, Inc. Common Stock
ISEE
|
$9.33M |
| 2 |
Palisade Bio
PALI
|
$7.43M |
| 3 |
Crinetics Pharmaceuticals
CRNX
|
$7.16M |
| 4 |
ESSA Pharma
EPIX
|
$6.1M |
| 5 |
electroCore
ECOR
|
$5.95M |
Sector Composition
| 1 | Healthcare | 83.78% |
| 2 | Financials | 5.42% |
| 3 | Technology | 2.08% |
| 4 | Industrials | 1.49% |
| 5 | Communication Services | 1.31% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Myriad Genetics
MYGN
$615M
| $5.1M | 1.34% |
158,000
-13,242
| -8% | -$428K |
|
27
Natera
NTRA
$23.1B
| $5.07M | 1.33% |
45,500
+12,270
| +37% | +$1.37M |
|
28
MEI Pharma
MEIP
$139M
| $5.05M | 1.32% |
91,403
| – | – |
|
|
MBTC
29
DELISTED
Nocturne Acquisition Corporation Ordinary Shares
MBTC
| $4.99M | 1.31% |
500,000
| – | – |
|
|
30
Keros Therapeutics
KROS
$633M
| $4.99M | 1.31% |
+126,000
| New | +$4.99M |
|
31
Spyre Therapeutics
SYRE
$1.03B
| $4.85M | 1.27% |
24,388
| – | – |
|
32
Castle Biosciences
CSTL
$683M
| $4.82M | 1.26% |
72,500
+3,500
| +5% | +$233K |
|
33
Varex Imaging
VREX
$484M
| $4.46M | 1.17% |
158,000
+16,681
| +12% | +$470K |
|
|
AVDL
34
Avadel Pharmaceuticals
AVDL
$1.53B
| $4.32M | 1.13% |
440,589
| – | – |
|
|
35
X4 Pharmaceuticals
XFOR
$78.6M
| $4.26M | 1.12% |
+26,820
| New | +$4.26M |
|
|
AFMD
36
DELISTED
Affimed
AFMD
| $4.11M | 1.08% |
+66,500
| New | +$4.11M |
|
|
37
Crinetics Pharmaceuticals
CRNX
$3.35B
| $4.06M | 1.07% |
193,000
-340,033
| -64% | -$7.16M |
|
38
Illumina
ILMN
$15.7B
| $4.06M | 1.06% |
10,280
+2,056
| +25% | +$811K |
|
|
EUCR
39
DELISTED
Eucrates Biomedical Acquisition Corp. Ordinary Shares
EUCR
| $3.91M | 1.03% |
400,000
| – | – |
|
40
EyePoint Pharmaceuticals
EYPT
$966M
| $3.86M | 1.01% |
370,551
| – | – |
|
|
BCYC
41
Bicycle Therapeutics
BCYC
$496M
| $3.83M | 1% |
+92,000
| New | +$3.83M |
|
42
Arcturus Therapeutics
ARCT
$485M
| $3.82M | 1% |
+80,000
| New | +$3.82M |
|
43
BridgeBio Pharma
BBIO
$10.2B
| $3.7M | 0.97% |
+79,000
| New | +$3.7M |
|
|
RCOR
44
DELISTED
Renovacor, Inc.
RCOR
| $3.52M | 0.92% |
388,845
-365,029
| -48% | -$3.3M |
|
|
ICAD
45
DELISTED
iCAD Inc
ICAD
| $3.44M | 0.9% |
+320,000
| New | +$3.44M |
|
|
PROF
46
Profound Medical
PROF
$124M
| $3.44M | 0.9% |
235,000
+24,720
| +12% | +$362K |
|
47
Travere Therapeutics
TVTX
$1.93B
| $3.42M | 0.9% |
141,000
-29,484
| -17% | -$715K |
|
|
MORF
48
DELISTED
Morphic Holding, Inc. Common Stock
MORF
| $3.4M | 0.89% |
60,000
+19,459
| +48% | +$1.1M |
|
49
Xenon Pharmaceuticals
XENE
$3.02B
| $3.3M | 0.87% |
216,000
+61,000
| +39% | +$932K |
|
50
Verrica Pharmaceuticals
VRCA
$48.2M
| $3.2M | 0.84% |
25,624
-26,889
| -51% | -$3.36M |
|